OUR PIPELINE

BioInvent has three proprietary antibodies in or close to clinical development to fight various cancers.

 


In addition, BioInvent has a number of research stage projects that we consider promising; especially in the field of immuno-oncology.

READ MORE

F.I.R.S.T.™

  • Enables combined target and drug discovery
  • No prior knowledge of the target is required
  • Allows for direct functional screening
  • Identifies disease targets that:
    • have a higher level of protein expression without a corresponding increase in mRNA expression
    • include post-translational modifications
    • are generated through protein-protein interactions

READ MORE

Press Releases

MEET US

25-27 Apr, 2016, BioTrinity, London, UK
10-11 May, 2016, BioEquity Europe, Copenhagen, Denmark

 

PRESENTATIONS

Finwire TV: BioInvent, March 29, 2016 Webcast (Swedish)

Aktiespararna, Jönköping, Sweden, March 15, 2016 Webcast (Swedish)

SEK